FAQ on Kairos Pharma Ltd.'s KROS101 Preclinical Data Presentation at ASCO 2025
Summary
What is KROS101 and what does it do?
KROS101 is an investigational small molecule GITR ligand agonist developed by Kairos Pharma Ltd. It enhances effector T cell activity and reduces immune-suppressive T reg cells, promoting tumor infiltration and boosting cytotoxicity.
Why is the preclinical data on KROS101 significant?
The data demonstrates KROS101’s dual mechanism of action in enhancing immune response and tumor destruction, outperforming previous treatments like TRX518 in preclinical settings, indicating its potential as a breakthrough in cancer immunotherapy.
How does KROS101 compare to TRX518?
KROS101 outperformed TRX518, a prior anti-GITR antibody, in promoting tumor infiltration, boosting cytotoxicity, and preventing T cell exhaustion, as shown in the preclinical study presented at ASCO 2025.
Who is behind the development of KROS101?
Kairos Pharma Ltd., a Los Angeles-based company specializing in oncology therapeutics, is developing KROS101. The company focuses on overcoming drug resistance and immune suppression in cancer.
Where can I find more information about Kairos Pharma Ltd. and its research?
More information is available on the company’s website at www.KairosPharma.com and in the company’s newsroom at https://ibn.fm/KAPA.
What are the next steps for KROS101?
While the preclinical data is promising, the next steps would involve advancing KROS101 through clinical trials to evaluate its safety and efficacy in humans, though specific timelines were not provided in the content.
What other treatments is Kairos Pharma Ltd. developing?
Kairos Pharma Ltd. is also developing ENV105, an antibody targeting CD105, currently in Phase 2 clinical trial for castrate resistant prostate cancer and a Phase 1 trial for lung cancer, aiming to reverse drug resistance in various cancer types.
Where was the preclinical data on KROS101 presented?
The preclinical data on KROS101 was presented at the ASCO 2025 Annual Meeting, highlighting its potential in cancer immunotherapy.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 110676